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SongFeng Xu, XiuChun Yu*, Ming Xu and ZhiHou FuAbstract
Background: Giant cell tumors (GCT) around the knee are common and pose a special problem of reconstruction
after tumor excision, especially for grade III GCT. We questioned whether en bloc resection and reconstruction with
alcohol inactivated autograft-prosthesis composite would provide (1) local control and long-term survival and
(2) useful limb function in patients who had grade III GCT around the knee.
Methods: We retrospectively reviewed eight patients (5 males and 3 females) treated with this procedure with
mean age of 31 years (range 20 to 43 years) from Jan 2007 to Oct 2008. 5 lesions were located in distal femur
and 3 in proximal tibia. 4 patients were with primary tumor and the other 4 with recurrence. 2 patients showed
pathological fracture.
Results: Mean Follow-up is 54 months ranging from 38 to 47 months. No recurrence, metastasis, prosthesis loosening
were found. The mean healing time between autograft and host bone was 5.5 months. The mean MSTS score was
26.3 (88%) ranging from 25 to 29. The mean ISOLS composite graft score was 32.8 (88.5%) ranging from 28 to
35. Creeping substitution is possibly the main way in bony junction. The healing time in femoral lesion is faster
than that in tibial lesion.
Conclusions: The technique of alcohol inactivated autograft-prosthesis composite could be able to achieve
satisfactory oncological and functional outcomes in Grade III GCT.
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Giant cell tumor (GCT) of bone is aggressive, potentially
malignant lesion which remains a difficult and challen-
ging management problem. The ends of long bones in
skeletally mature individuals are involved in more than
80% of cases and 75% of them occur around the knee
joint [1]. The reconstruction of large bone defects and
restoration of joint function resulting from resection of
aggressive grade III GCT around knee remains a challen-
ging problem.
Since the local behavior of giant cell tumors can be ag-
gressive and they have a greater risk of local recurrence,
some authors advocate en bloc resection and reconstruc-
tion for these grade III lesions from the point of view of* Correspondence: yxch48@vip.sina.com
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reproduction in any medium, provided the orpreventing local recurrence rate and preserving joint func-
tion [2,3]. Three most popular reconstructive methods are
endoprosthesis, allograft–prosthesis composite and bio-
logical reconstruction. However, each of these methods
has its short- and long-term advantages and disadvantages
[4]. We noted that mega-prosthesis is a feasible method
for treating GCT of grade III around the knee, and com-
plications related to which were mainly prosthesis loosen-
ing and limb shortening, increase gradually with longer
survival time [5].
We questioned whether en bloc resection and recon-
struction with alcohol inactivated autograft-prosthesis
composite would provide (1) local control and long-term
survival and (2) useful limb function in patients who had
grade III GCT around the knee. To overcome possible dis-
advantages of the above methods, 8 patients with grade III
GCT around knee were treated with this method. TheThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vide both mechanical stability in early time and fine limb
function in long time on the basis of complete resection
and decreasing recurrence rate.
Methods
Collection of retrospective clinical data and the publica-
tion of the data were in accordance with local guidelines
for research ethics and were approved by General
Hospital of Ji'Nan Military Region. All patients had been
treated the procedure by the same chief surgeon (XCY)
and his assistants (SFX and MX) in the same institute.
All procedures were in compliance with the Helsinki
Declaration.
We retrospectively reviewed 8 patients with aggressive
GCT around knee who underwent reconstruction using
an autograft–prosthesis composite from Jan 2007 to Oct
2008 (Table 1). There were 5 males and 3 females with
an average age of 31 years (range 20–43 years). 5 lesions
located in distal femur and 3 in proximal tibia. 4 patients
were with primary tumor and the other 4 with recur-
rence. 2 patients were with pathological fracture. All
patients were diagnosed as GCT of Campanacci III de-
termined by biopsy and pathology.
The indications for a wide resection were extensive
tumor (Campanacci III [6]) invasion with or without
pathological fracture and rapid or large recurrent tumor
after intensive curettage. In addition, according to Yang’s
study [7], if the diameter of GCT lesion around the knee
is over 1/2 on CT transversal image, en bloc resection
and reconstruction should be chosen. All patients were
in line with the above criteria.
All patients underwent en bloc resection of tumor
and reconstruction with alcohol inactivated autograft–
prosthesis composite under epidural anesthesia. The do-
mestic rotating-hinged knee prosthesis (Lidakang, Beijing,
China) were chosen. The conventional anterormedial inci-
sion encircling the biopsy scar for the knee was used. A







Left distal femur No Recurrence 67
Right distal femur No Recurrence 60
Left distal femur Yes Primary 51
Left distal femur No Recurrence 48




Left proximal tibia No Primary 48
Right proximal
tibia
No Primary 48accepted. The surgical technique, taking the inactivated
autograft-prosthesis composite of distal femur as a sample,
was described as follows: (1) The lesion in distal femur was
resected according to tumor-free technique rules, and
then soft tissue and extraosseous tumor were cleared off
(Figure 1a). (2) The medullar cavity was reamed and in-
traosseous tumor was curetted with the distal femoral ar-
ticular surface removed (Figure 1b). (3) Preliminary screw
fixation was prepared with cemented technique. The pre-
pared autograft was then immerged into 99% alcohol for
30 minutes, retrieved and flushed with 3000 ml physio-
logical saline (Figure 1c). (4) After cylindrical reaming of
the proximal femur, the prosthesis was inserted and
cemented (Figure 1d). The long-stem femoral component
was inserted into the inactivated bone off the table by care-
fully pressurizing cement into the inactivated bone, using
the operator’s thumb to occlude the proximal medullar
canal. Any excess cement was removed from the protrud-
ing stem of the femoral component and from the distal
end of the inactivated bone. (5) After polymerization of
the cement, the composite prosthesis was cemented into
the host bone, and care was taken so no cement was
caught between the inactivated autograft and the host
bone. In all patients, autogenous iliac bone grafts were
placed at the inactivated autograft-host bone junction to
form extracortical grafting (Figure 1e).
For GCT in proximal tibia, we think it was important
to use the medial gastrocnemius muscle flap transfer to
minimize the rate of complication, such as infection and
skin necrosis (Figure 2b). The patellar tendon was su-
tured directly to the transposed flap to repair the exten-
sor mechanism. The continuity of intact side of tumor
bone with pathological fracture should be maintained
during the inactivation procedure. The larger bone frag-
ments should be cemented to inactivated tumor after al-
cohol inactivation.
Prophylactic antibiotics were administered for 48 hours.
Low-molecular-weight heparin was administered for 2 weeks.





Status at latest follow-
up
27 (90%) 33 (92%) Disease-free
26 (87%) 35 (97%) Disease-free
25 (83%) 28 (78%) Disease-free
25 (83%) 31 (86%) Disease-free
26 (87%) 30 (83%) Disease-free
29 (97%) 35 (97%) Disease-free
26 (87%) 30 (83%) Disease-free
27 (90%) 33 (92%) Disease-free
ab        c e
d
Figure 1 A patient with postoperative recurrence of bone giant cell tumor and pathological fracture in left distal femur (Case 4).
a Osteotomy was performed at 3 cm above the upper boder of tumor, b All tissue on the tumor bone was removed and the medullary cavity
was drilled through, c The tumor bone was infused in dehydrated alcohol for 30 minutes, d The deactivated autograft was adjusted and
combined with prothesis using bone cement with which the bone defect filled e The autograft-prothesis composite was fixed with host bone
with the junction site tied around autogenous bone as extracortical bone grafting.
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tibia for 3 weeks. After that, partial weight bearing was
allowed initially, and then weight bearing using two elbow
crutches was allowed. Full weight bearing with no support
was allowed at the end of 3 months. Plain anteroposterior
and lateral radiographic examinations were done every
3 months for two years, bi-annually for a further three
years and annually thereafter.
Limb function was evaluated with the Musculoskeletal
Tumor Society (MSTS) rating scales, which comprise six
items, namely pain, function, emotional acceptance, sup-
ports, walking and gait. The highest possible score is 30
and 5 points being allocated to each item [8]. Bone healing
features were evaluated with the International Society of
Limb Salvage (ISOLS) composite grafts evaluation method,
which assesses bone remodeling, interface, anchorage,a
b       c  d   
Figure 2 A patient with postoperative recurrence of GCT in right prox
GCT lesion with soft tissue mass was over 1/2 on CT transversal image, b E
should be noted during operation, c Destruction of bone was shown on p
prosthesis composite was shown, e Bone callus was obvious 6 weeks after
after 1 year. g After 3 years, the autograft-composite was in good position.implant, fusion, resorption, fracture, graft shortening, fix-
ation on plain X-ray radiographs and rates these items
from 1 to 4 points [9].Results
All operations were performed successfully and the mean
operating time was 2 hours and a half. No intraoperative
complications occurred and the mean bleeding amount
was about 450 ml.
The mean follow-up was for 54 months ranging from 38
to 47 months. 6 were followed for more than 4 years, and
2 were for more than 5 years. No recurrence, metastasis
or composite removal occurred at the end of follow-up.
No infection, composite fracture or prosthesis loosening
was found. All patients were disease-free.e  f  g
imal tibia (Case 6). a Preoperative CT image showed the diameter of
xtracortical grafting and medial gastrocnemius muscle flap transfer
reoperative X-ray image, d After one week, good position of autograft-
operation, f Osteotomy line dismissed and bone healing was found
MSTS score was 29 and ISOLS score was 35.
Figure 3 A patient with postoperative recurrence of bone giant cell tumor in right distal femur was treated with wide resection of tumor
and replacement of alcohol-deactived autograft-prothesis composite (Case 2). (a) The preoperative X-ray image showed the
osteolytic lesion encroaching articular surface and thinner cortical bone in medial condyle of right femur, (b) The preoperative CT image showed the
lesion exceeding half of femoral diameter, (c-d) At 9-month after operation, the motion of right knee joint was 0°- 90°, (e) At 25-month after operation,
the X-ray image showed bone healing and satisfactory space of prothesis without lossening and breakage, and the ISOLS graft score is 35.
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29 (Figure 3). The mean range of motion (ROM) in the knee
joint was 100° ranging from 70° to 130°. The mean ISOLS
composite graft score was 32.8 (88.5%) ranging from 28 to
35.3 in proximal tibia were over 30 (Figure 2). Bone union
in composite-host bone junction site was found in
all patients. The average union time was 5.5 months (range
4–7.5 months). No nonunion, loosening or resorption of
host bone was found in all patients.
Discussion
The ideal aim in the management of GCT is to eradicate
the tumor and preserve joint function [10]. Wide resection
is the treatment of choice, especially for GCT with extensive
destruction of bone structure, recurrence, pathological frac-
tures and difficulty in reconstruction after intralesional cur-
ettage [7,10]. Progress in biomedical engineering along with
better surgical techniques has improved overall 10-year
prosthetic survival rate after endoprosthetic replacement
from 20% to 80% in the past three decades. As
the survival of prosthesis improves, the major concern is its
reconstruction longevity. However, it is difficult to overcome
the mentioned disadvantages of prosthesis. It was believed
by us that the alcohol inactivated autograft-prosthesis com-
posite could be chosen for Campanacci grade III GCT of
which the lesion diameter was over 1/2 on CT transversal
image, with or without recurrence and pathological fracture.The main aims of bone and joint reconstruction are:
(1) skeletal stabilization, (2) restoration of length and align-
ment, and (3) preservation or reconstruction of optimum
function [11]. It has been recommended that the most
effective and easiest way to reconstruct the extensor mech-
anism sometimes around the knee is to use an allograft-
prosthetic composite [12].
Achieving complete ablation of the tumor and preserving
a functional extremity at the same time proves to be a diffi-
cult task due to the various anatomical factors unique to this
site. Difficulties in the local control of giant cell tumors with
Campanacci III as well as high rate of local recurrence fol-
lowing initial surgery have led the investigators to use differ-
ent surgical modalities of reconstruction. At present, the
most popular biological reconstruction method following
skeletal tumor resection is allografting [13-16]. However,
there are problems relating to infectious transmission, im-
munological reaction and refusal based on social or religious
beliefs especially in Asian countries. Under these circum-
stances, recycled tumor bone autografts are widely used as
an alternative to bone allografts. Devitalized bone autograft
is particularly well suited in the region where allografts are
not readily available [17]. Techniques that are capable of
destroying tumor cells in resected bone include (1) irradi-
ation [14,16], (2) autoclaving [18], (3) pasteurization [19,20],
(4) freezing-thawing with liquid nitrogen [21] and alcohol
inactivation [22,23]. Harrington et al. [18] reported that the
Table 2 Literature review of autograft/allograft-prosthesis composite for neoplasms around knee








Infection rate Nonunion rate
Current series Around knee 8 54 GCT Autograft-prosthesis composite 100% 88% 0 0
Song (2012) [20] Proximal tibia 25 >10 years Malignant tumors Pasteurized autograft-prosthesis
composite
68.7% 83.6% 20% NA
Gilbert (2009) [13] Proximal tibia 12 49 NA Allograft-prosthesis composite NA 81% 8.3% 25%
Donati (2008) [15] Proximal tibia 62 72 56 malignant tumors Allograft-prosthesis composite 73% 90.4% 24.2% 12.9%
4 GCT
2 failure operation
Jeon (2007) [19] Distal femur 15 56 Osteosarcoma Pasteurized autograft-prosthesis
composite
100% 86% 0 33%
Biau (2007) [14] Proximal tibia 26 128 NA Irradiated allograft-prosthesis
composite
79.4% NA 23% 73%
Wunder (2001) [16] Around knee 6 NA Bone sarcoma Irradiated allograft-prosthesis
composite
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support a joint arthroplasty and to allow early weight-
bearing with a low risk of pseudarthrosis or late fatigue frac-
ture. Jeon et al. [19] treated 15 distal femoral osteosarcoma
patients who underwent reconstructions using pasteurized
autograft–prosthesis composite. They found union of the
osteotomy site was identified in ten patients (67%) of whom
the average union time for junction sites was 16 months.
Nonunion was identified in five patients, who had cemented
fixation and a relatively long stem length in host bone. Loos-
ening of the stem was found in three patients. Resorption of
host bone was detected in two patients with noncemented
fixation. Biau et al. [14] reported on irradiated allograft-
prosthesis composites for proximal tibia reconstruction, it
yielded poor results for proximal tibial reconstruction as
complications and failures were common.
Compared to other methods, alcohol inactivation method
is considered on the same level of safety in oncological con-
trol, which superiorities are economic-applicable to patients
and the well fitness of bone graft with the defects. The ra-
tionale for this alcohol inactivated autograft-prosthesis
composite combined the suitable bone and mega-
prosthesis is the cumulative advantage provided by the bio-
logical properties of the former with the mechanical endur-
ance of the latter. As shown in Table 2, there were no
nonunion in our alcohol inactivated autograft group, better
than that of allograft (25% [13], 12.9% [15]), irradiated allo-
graft (73% [15], 50% [16]) and pasteurized autograft (33%
[19]). No infection was found in our group, while 8.3-24.2%
[13,15] in allograft. The MSTS score was 26.4 (88%) in our
group which was near to that of allograft (90.4% [15]), bet-
ter than that of pasteurized autograft (86% [19]) and irradi-
ated allograft (67% [16]).
The disadvantage of alcohol inactivated bone is that it
needs a long time to accomplish revascularization and to in-
tegrate with surrounding bone. The rationality of alcohol in-
activation is that alcohol could devitalize the tumor bone
shell. The tumor cells had been devitalized when the in-
growth of surrounding vessels occurre [24]. Our previous
studies showed that continuous bone callus presented after
8 weeks and complete bony healing showed after 12 weeks
in rabbit femur [25]. The irradiated allograft presented the
likely bony healing process of creeping substitution with the
bone formation rate of 1 cm per 10 months [17]. In this
study, according to the dynamic imaging observation and
ISOLS composite scoring, the new bone originated from
host bone and the bone healing time in femur is about 4 to
6 months and that in tibia about 6–8 months. We hold the
viewpoint that creeping substitution is possibly the main
way in bony junction and the healing time in femur is faster
than that in tibia.
Metal prosthesis resulted in artifacts during CT and
MRI imaging, which impaired the evaluation of bone
healing. On this consideration, X-ray imaging waschosen to evaluate bone healing according to ISOLS
composite grafts evaluation method [26]. The mean
ISOLS composite graft score was 32.8 (88.5%) as good in
our group ranging from 28 to 35 which were all over 28
as better. The average union time was 5.5 months (range
4–7.5 months) which was better than that of allograft
(7.4 months) [27] and pasteurized autograft (16 months)
[19]. The alcohol inactivated autograft was superior to
allograft in bone healing. In addition, it was recommended
by us that good anatomic reduction and specially made
long stem play important roles in bone healing. If the
lesion extent was over half of the affected bone and the
host bone with enough strength, the patient should
undergo en bloc resection of tumor and reconstruction
with alcohol inactivated autograft–prosthesis composite.
There are limitations in this study, such as small
amount of patients and the less than 5 years’ follow-up,
which might result in biased result. The multi-centric
randomized controlled study with large samples should
be considered.
Conclusions
Based on our outcomes, we believe alcohol inactivated
autograft-prosthesis composite is a reasonable option as
a limb salvage procedure for Grade III GCT around
knee. By using this technique we have been able to
achieve satisfactory oncological and functional outcomes
in these patients.
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